Premium
A Randomized, Double‐blind, Placebo‐controlled Clinical Trial Examining the Effects of Green Tea Extract on Systemic Lupus Erythematosus Disease Activity and Quality of Life
Author(s) -
Shamekhi Z.,
Amani R.,
Habibagahi Z.,
Namjoyan F.,
Ghadiri Ata,
Saki Malehi A.
Publication year - 2017
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5827
Subject(s) - medicine , camellia sinensis , placebo , quality of life (healthcare) , systemic disease , randomized controlled trial , lupus erythematosus , clinical trial , disease , traditional medicine , immunology , pathology , alternative medicine , botany , nursing , antibody , biology
Antiinflammatory and immunomodulatory benefit of green tea ( Camellia sinensis ) in autoimmune disease has been proven in recent studies. The objective of this study was to assess the effects of green tea on disease activity and quality of life in systemic lupus erythematosus patients. A randomized controlled trial on subjects with lupus was conducted, and 68 patients in the age range of 39.1 ± 10.3 years and body mass index of 25.7 ± 5.21 kg/m 2 completed the 12‐week study. Patients were randomly divided into two groups of intervention (1000 mg green tea extract, two capsules/day) and control (1000 mg of starch, two capsules/day). Main outcome measure, systemic lupus erythematosus disease activity, was assessed by the systemic lupus erythematosus disease activity index at the first and after 3 months of intervention. In addition, patient's quality of life was evaluated by short form of quality‐of‐life questionnaire at baseline and after 3 months. Green tea extract supplementation significantly reduced disease activity in lupus patients ( p < 0.004); in addition, it significantly increased the vitality ( p < 0.006) and general health ( p < 0.01). This study showed that daily consumption of green tea extracts for 12 weeks improves the systemic lupus erythematosus disease activity as well as some aspects of quality of life. Copyright © 2017 John Wiley & Sons, Ltd.